Ocular Therapeutix, Inc.
OCUL
$7.45
-$0.49-6.17%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.41% | 2.28% | 8.26% | 10.47% | 5.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.41% | 2.28% | 8.26% | 10.47% | 5.16% |
| Cost of Revenue | 140.14% | 135.51% | 85.18% | 38.22% | 20.79% |
| Gross Profit | -804.21% | -1,663.50% | -1,048.93% | -181.68% | -479.17% |
| SG&A Expenses | 47.30% | 27.43% | 53.24% | 21.88% | -8.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.13% | 79.10% | 67.89% | 29.14% | 4.23% |
| Operating Income | -152.24% | -139.40% | -111.91% | -40.21% | -3.56% |
| Income Before Tax | -65.60% | -6,972.29% | -111.67% | -113.89% | -88.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.60% | -6,972.29% | -111.67% | -113.89% | -88.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.60% | -6,972.29% | -111.67% | -113.89% | -88.01% |
| EBIT | -152.24% | -139.40% | -111.91% | -40.21% | -3.56% |
| EBITDA | -159.92% | -145.79% | -114.05% | -39.11% | -1.18% |
| EPS Basic | 16.79% | -3,261.54% | 0.38% | -25.37% | -71.51% |
| Normalized Basic EPS | 16.78% | -17.96% | 0.36% | 28.66% | -71.53% |
| EPS Diluted | 16.79% | 13.15% | 0.38% | -25.37% | -46.10% |
| Normalized Diluted EPS | 16.78% | -26.48% | 0.36% | 28.66% | -84.40% |
| Average Basic Shares Outstanding | 99.00% | 110.39% | 112.47% | 70.60% | 9.63% |
| Average Diluted Shares Outstanding | 99.00% | 96.13% | 112.47% | 70.60% | 1.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
